CSTL Castle Biosciences

Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fifth Consecutive Year

Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fifth Consecutive Year

Castle also earns national recognition through three additional Top Workplaces Culture Excellence Awards — Employee Appreciation, Employee Well-Being and Professional Development

FRIENDSWOOD, Texas, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has been recognized by the Houston Chronicle as a Houston Top Workplace, which celebrates people-focused, standout workplace cultures. This marks the fifth consecutive year the Company has been ranked among the Houston metro area’s esteemed workplaces. Castle also earned three Culture Excellence awards in the areas of Employee Appreciation, Employee Well-Being and Professional Development.

“Our people-first culture is the foundation of everything we do at Castle, and it's our talented, dedicated employees who make it a great place to work," said Derek Maetzold, president and chief executive officer of Castle Biosciences. "Having worked in healthcare for more than 40 years, I can say with confidence that the people who call Castle home are truly special. They are deeply committed to our vision of transforming disease management by keeping people first, and together, we're making a real impact on the lives of patients we serve. This is a place where purpose and compassion drive innovation, and I'm honored to be part of such an exceptional team.”

Castle earned its first Top Workplaces designation in November 2021 and has maintained its strong culture of excellence while more than doubling its workforce since that time. This year alone, Castle has received 13 Top Workplaces awards, which include the following announced earlier this year:

  • Top Workplaces USA (four consecutive years)
  • Top Workplaces Healthcare Industry (three consecutive years), ranking third among other recognized companies in its size bracket in 2025
  • Top Workplaces Arizona, from AZ Central (four consecutive years)
  • Top Workplaces Greater Pittsburgh, from The Pittsburgh Post-Gazette
  • Five Top Workplaces Culture Excellence Awards in the areas of Innovation, Work-Life Flexibility, Compensation & Benefits, Leadership and Purpose & Values

The Top Workplaces designation is based exclusively on anonymous employee feedback gathered through a third-party survey administered by Energage. The confidential survey measures several aspects of workplace culture, including whether employees feel respected and supported, enabled to grow and empowered to execute.

The comprehensive list of 2025 Houston Chronicle Top Workplaces can be viewed . Additional information regarding the Culture Excellence Awards is available on the .

About Castle Biosciences

Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. With a primary focus in dermatologic and gastroenterological disease, we develop personalized, clinically actionable solutions that help improve disease management and patient outcomes.

We put people first—empowering patients and clinicians and informing care decisions through rigorous science and advanced molecular tests that support more confident treatment planning. To learn more, visit  and connect with us on , , and . 

DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, AdvanceAD-Tx, TissueCypher, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.

Investor Contact:

Camilla Zuckero

Media Contact:

Allison Marshall

Source: Castle Biosciences Inc.



EN
17/11/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Castle Biosciences

 PRESS RELEASE

Prospective, Multi-center Study Published in Future Oncology Demonstra...

Prospective, Multi-center Study Published in Future Oncology Demonstrates DecisionDx®-Melanoma’s i31-SLNB Result Outperforms Staging Criteria in Identifying Patients with Cutaneous Melanoma Below the 5% NCCN Threshold for Forgoing SLNB Among all patients studied, 2.6% nodal positivity and 97.8% three-year recurrence-free survival (RFS) was observed in those predicted to have less than 5% risk of a positive sentinel lymph node (SLN) by DecisionDx-Melanoma’s i31-SLNB Only 1.4% SLN positivity was observed in patients with T1b–T2a tumors predicted to have less than 5% risk The Company will ho...

 PRESS RELEASE

DecisionDx®-Melanoma’s i31-SLNB: Report from the Largest Prospective M...

DecisionDx®-Melanoma’s i31-SLNB: Report from the Largest Prospective Multicenter Study to Date Confirms 2.6% Nodal Positivity in Patients Predicted to Have Less Than 5% Risk Study results were recently shared at the Society of Surgical Oncology (SSO) 2026 Annual Meeting in Phoenix. NCCN Cutaneous Melanoma Guidelines recommend avoiding a sentinel lymph node (SLN) biopsy (SLNB) if the predicted SLN positivity rate is less than 5%. This report shows that patients with a less than 5% predicted risk of SLN positivity by the DecisionDx-Melanoma test had an actual SLN positivity rate of just 2.6%...

 PRESS RELEASE

Castle Biosciences to Present Data at SSO 2026 on DecisionDx®-Melanoma...

Castle Biosciences to Present Data at SSO 2026 on DecisionDx®-Melanoma’s i31-SLNB, Identifying T1b–T2a Melanoma Patients Who May Safely Avoid SLNB FRIENDSWOOD, Texas, March 04, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that new data evaluating DecisionDx-Melanoma’s i31-SLNB test result for prediction of sentinel lymph node (SLN) positivity will be presented at the Society of Surgical Oncology (SSO) 2026 Annual Meeting, being held March 5-7 in Phoenix. “The initial reports ...

 PRESS RELEASE

Castle Biosciences Announces Grand Opening of New Corporate Headquarte...

Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas FRIENDSWOOD, Texas, March 03, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will host a grand opening celebration for its new corporate headquarters on Tuesday, March 24, 2026, at 3:00 p.m. Central time. The event will take place at the Company’s new campus located at 1500 West Parkwood Avenue in Friendswood, Texas, and will bring together employees, community partners and oth...

 PRESS RELEASE

Castle Biosciences Reports Fourth Quarter and Full–Year 2025 Results

Castle Biosciences Reports Fourth Quarter and Full–Year 2025 Results 2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 37% over 2024 Exceeded 2025 guidance with full-year revenue of $344 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the fourth quarter and year ended Dec. 31, 2025.“We closed out an outstanding year...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch